297 related articles for article (PubMed ID: 37086394)
1. Enhancing prognostication and personalizing treatment of extranodal marginal zone lymphoma.
Alderuccio JP; Lossos IS
Expert Rev Hematol; 2023 May; 16(5):333-348. PubMed ID: 37086394
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathogenesis and histologic and clinical features of extranodal marginal zone lymphomas of mucosa-associated lymphoid tissue type.
Kuper-Hommel MJ; van Krieken JH
Leuk Lymphoma; 2012 Jun; 53(6):1032-45. PubMed ID: 21988643
[TBL] [Abstract][Full Text] [Related]
3. Management of marginal zone lymphomas.
Merli M; Arcaini L
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):676-687. PubMed ID: 36485086
[TBL] [Abstract][Full Text] [Related]
4. An international analysis evaluating frontline bendamustine with rituximab in extranodal marginal zone lymphoma.
Alderuccio JP; Arcaini L; Watkins MP; Beaven AW; Shouse G; Epperla N; Spina M; Stefanovic A; Sandoval-Sus J; Torka P; Alpert AB; Olszewski AJ; Kim SH; Hess B; Gaballa S; Ayyappan S; Castillo JJ; Argnani L; Voorhees TJ; Saba R; Chowdhury SM; Vargas F; Reis IM; Kwon D; Alexander JS; Zhao W; Edwards D; Martin P; Cencini E; Kamdar M; Link BK; Logothetis CN; Herrera AF; Friedberg JW; Kahl BS; Luminari S; Zinzani PL; Lossos IS
Blood Adv; 2022 Apr; 6(7):2035-2044. PubMed ID: 35196377
[TBL] [Abstract][Full Text] [Related]
5. A unique description of stage IV extranodal marginal zone lymphoma (EMZL) in an adolescent associated with gamma heavy chain disease.
Mittal N; Zhu B; Gaitonde S; Lu Y; Schmidt ML
Pediatr Blood Cancer; 2015 May; 62(5):905-8. PubMed ID: 25663537
[TBL] [Abstract][Full Text] [Related]
6. CD5 expression in marginal zone lymphoma predicts differential response to rituximab or bendamustine/rituximab.
Hsu A; Kurt H; Zayac AS; Olszewski AJ
Leuk Lymphoma; 2022 Jan; 63(1):31-42. PubMed ID: 34467833
[TBL] [Abstract][Full Text] [Related]
7. Bendamustine-rituximab regimen in untreated indolent marginal zone lymphoma: experience on 65 patients.
Morigi A; Argnani L; Lolli G; Broccoli A; Pellegrini C; Nanni L; Stefoni V; Coppola PE; Carella M; Casadei B; Sabattini E; Cavo M; Zinzani PL
Hematol Oncol; 2020 Oct; 38(4):487-492. PubMed ID: 32594531
[TBL] [Abstract][Full Text] [Related]
8. Outcome and prognostic factors in ocular adnexal lymphoma.
Nola M; Lukenda A; Bollmann M; Kalauz M; Petrovecki M; Bollmann R
Croat Med J; 2004 Jun; 45(3):328-32. PubMed ID: 15185428
[TBL] [Abstract][Full Text] [Related]
9. Dual institution experience of extranodal marginal zone lymphoma reveals excellent long-term outcomes.
Starr AG; Caimi PF; Fu P; Massoud MR; Meyerson H; Hsi ED; Mansur DB; Cherian S; Singh AD; Cooper BW; De Lima MJ; Lazarus HM; Gerson SL; Jagadeesh D; Smith MR; Dean RM; Pohlman BL; Hill BT; William BM
Br J Haematol; 2016 May; 173(3):404-12. PubMed ID: 26953041
[TBL] [Abstract][Full Text] [Related]
10. Marginal zone B-cell lymphoma: lessons from Western and Eastern diagnostic approaches.
Nakamura S; Ponzoni M
Pathology; 2020 Jan; 52(1):15-29. PubMed ID: 31757436
[TBL] [Abstract][Full Text] [Related]
11. A single-center analysis of patients with extranodal marginal zone lymphoma of the breast.
Iyer SG; Kuker R; Florindez JA; Saul E; Trabolsi A; Rodriguez G; Chapman JR; Lossos IS; Alderuccio JP
Leuk Lymphoma; 2022 Mar; 63(3):591-598. PubMed ID: 34672247
[TBL] [Abstract][Full Text] [Related]
12. Front-line management of indolent non-Hodgkin lymphoma in Australia. Part 2: mantle cell lymphoma and marginal zone lymphoma.
Cheah CY; Opat S; Trotman J; Marlton P
Intern Med J; 2019 Sep; 49(9):1070-1080. PubMed ID: 30816618
[TBL] [Abstract][Full Text] [Related]
13. Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Zucca E; Arcaini L; Buske C; Johnson PW; Ponzoni M; Raderer M; Ricardi U; Salar A; Stamatopoulos K; Thieblemont C; Wotherspoon A; Ladetto M;
Ann Oncol; 2020 Jan; 31(1):17-29. PubMed ID: 31912792
[No Abstract] [Full Text] [Related]
14. Marginal Zone Lymphoma: State-of-the-Art Treatment.
Sindel A; Al-Juhaishi T; Yazbeck V
Curr Treat Options Oncol; 2019 Dec; 20(12):90. PubMed ID: 31807935
[TBL] [Abstract][Full Text] [Related]
15. Primary extranodal marginal zone B-cell lymphoma of the female genital tract: a case report and literature review.
Heeren JH; Croonen AM; Pijnenborg JM
Int J Gynecol Pathol; 2008 Apr; 27(2):243-6. PubMed ID: 18317217
[TBL] [Abstract][Full Text] [Related]
16. Marginal zone lymphoma of the colon: case series from a single center and SEER data review.
Trabolsi A; Alderuccio JP; Florindez J; Rodriguez G; Saul E; Iyer SG; Chapman JR; Poveda J; Sussman DA; Lossos IS
Leuk Lymphoma; 2022 May; 63(5):1160-1166. PubMed ID: 34927537
[TBL] [Abstract][Full Text] [Related]
17. Rituximab Monotherapy or in Combination with Bendamustine Is Not Inferior to Rituximab-CHOP Regimen in the Treatment of Patients with Splenic Marginal Zone Lymphoma in the Real Life.
Mulas O; Caocci G; Dessì D; Mantovani D; Moi G; Cabras MG; La Nasa G
Acta Haematol; 2021; 144(3):322-326. PubMed ID: 32892194
[TBL] [Abstract][Full Text] [Related]
18. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma.
Laribi K; Tempescul A; Ghnaya H; Denizon N; Besançon A; Anghel A; Farhi J; Truong C; Lemaire P; Poulain S; Bolle D; Ianotto JC; Baugier de Materre A
Hematol Oncol; 2017 Dec; 35(4):536-541. PubMed ID: 27443419
[TBL] [Abstract][Full Text] [Related]
19. International multicentre retrospective cohort study of ocular adnexal marginal zone B-cell lymphoma.
Hindsø TG; Esmaeli B; Holm F; Mikkelsen LH; Rasmussen PK; Coupland SE; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Sjö LD; Vemuganti GK; Thuro BA; Heegaard S
Br J Ophthalmol; 2020 Mar; 104(3):357-362. PubMed ID: 31177189
[TBL] [Abstract][Full Text] [Related]
20. The many faces of marginal zone lymphoma.
Zinzani PL
Hematology Am Soc Hematol Educ Program; 2012; 2012():426-32. PubMed ID: 23233614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
